BioSig AI Sciences Closed $2.2M in Seed Round Investment

BioSig Technologies, a firm revolutionizing intra-cardiac signal visualization, has announced a successful $2.2M seed funding round for its subsidiary, BioSig AI Sciences (BAIS).

BAIS plans to collaborate with BioSig's leading technology team and external partners to expedite the research and development of an AI medical device platform.

BioSig's Chairman, CEO, and Founder, Ken Londoner, expressed his ambition for the company to be at the forefront of integrating AI and machine learning into electrophysiology devices, fueling the market's expected growth. Londoner emphasized the interest and enthusiasm generated by their current platform and future plans.

The initial partnership between BioSig and Reified Labs in 2019 has already led to several patent applications and a research publication on AI-enhanced electrocardiogram lead placement mapping. BAIS is now exploring how advanced language models, similar to Chat-GPT, can assist hospital partners in tackling their present challenges.

Data Bridge Market Research predicts the AI in healthcare market to surge from $9.6 billion in 2022 to $272.9 billion by 2030, indicating a CAGR of 51.9% during this period.

The integration of AI and machine learning in electrophysiology devices is powering substantial expected growth for this market, and we intend to be a leader in developing applications of these technologies, - said Ken Londoner, Chairman, CEO and Founder of BioSig.

About: BioSig Technologies is an advanced medical technology company bringing never-before-seen insights to the treatment of cardiovascular arrhythmias.